BUZZ-Cyclerion Therapeutics 在麻省理工学院开发抑郁症药物的交易中一跃而起

路透中文

Sep 24

BUZZ-Cyclerion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 在麻省理工学院开发抑郁症药物的交易中一跃而起

9月24日 - ** 药物开发商Cyclerion Therapeutics CYCN.O股价盘前上涨43%至4.33美元

** 该公司在周二晚些时候表示， (link)，在与麻省理工学院签署许可协议后，它将作为一家专注于神经精神疾病的公司重新上市

** 该公司的主要项目是利用基于麻醉剂的技术来治疗难治性抑郁症

** 公司表示，中期试验预计将于 2026 年开始，并于 2027 年获得数据

** 截至上一交易日收盘，股价累计下跌 6.2

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569770289"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569770289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569770289?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-24 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569770289","market":"us","top_or_hot":-1,"title":"BUZZ-Cyclerion Therapeutics 在麻省理工学院开发抑郁症药物的交易中一跃而起","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 在麻省理工学院开发抑郁症药物的交易中一跃而起</title></head><body><p><span>9月24日</span><span> - </span>** 药物开发商Cyclerion Therapeutics <span>CYCN.O</span>股价盘前上涨43%至4.33美元</p><p>** 该公司在周二晚些时候表示， (link)，在与麻省理工学院签署许可协议后，它将作为一家专注于神经精神疾病的公司重新上市</p><p>** 该公司的主要项目是利用基于麻醉剂的技术来治疗难治性抑郁症</p><p>** 公司表示，中期试验预计将于 2026 年开始，并于 2027 年获得数据</p><p>** 截至上一交易日收盘，股价累计下跌 6.2</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Cyclerion Therapeutics 在麻省理工学院开发抑郁症药物的交易中一跃而起</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Cyclerion Therapeutics 在麻省理工学院开发抑郁症药物的交易中一跃而起\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-09-24 18:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 在麻省理工学院开发抑郁症药物的交易中一跃而起</title></head><body><p><span>9月24日</span><span> - </span>** 药物开发商Cyclerion Therapeutics <span>CYCN.O</span>股价盘前上涨43%至4.33美元</p><p>** 该公司在周二晚些时候表示， (link)，在与麻省理工学院签署许可协议后，它将作为一家专注于神经精神疾病的公司重新上市</p><p>** 该公司的主要项目是利用基于麻醉剂的技术来治疗难治性抑郁症</p><p>** 公司表示，中期试验预计将于 2026 年开始，并于 2027 年获得数据</p><p>** 截至上一交易日收盘，股价累计下跌 6.2</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nL3S3VB0LX:1","article_id":"2569770289","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569770289","pubTimestamp":1758709620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","CYCN":"Cyclerion Therapeutics, Inc."},"translate_title":"BUZZ-Cyclerion Therapeutics jumps in MIT deal to develop depression drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYCN":0.9},"content_text":"BUZZ-Cyclerion Therapeutics 在麻省理工学院开发抑郁症药物的交易中一跃而起9月24日 - ** 药物开发商Cyclerion Therapeutics CYCN.O股价盘前上涨43%至4.33美元** 该公司在周二晚些时候表示， (link)，在与麻省理工学院签署许可协议后，它将作为一家专注于神经精神疾病的公司重新上市** 该公司的主要项目是利用基于麻醉剂的技术来治疗难治性抑郁症** 公司表示，中期试验预计将于 2026 年开始，并于 2027 年获得数据** 截至上一交易日收盘，股价累计下跌 6.2(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}